Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MAGE-A1-specific T cell receptor-transduced autologous T-cell therapy - SignalOne Bio

Next Previous
X
Search
Drug Profile

MAGE-A1-specific T cell receptor-transduced autologous T-cell therapy - SignalOne Bio

Alternative Names: FH-MagIC TCR-T cell therapy; MAGE-A1-specific T cell receptor-transduced autologous CD8+ and CD4+ T-cells; MAGE-A1-specific TCR-transduced autologous T-cells

Latest Information Update: 27 Dec 2022

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator SignalOne Bio
  • Developer Fred Hutchinson Cancer Research Center; SignalOne Bio
  • Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Breast cancer; Non-small cell lung cancer; Solid tumours; Urogenital cancer

Most Recent Events

  • 13 Dec 2022 SignalOne Bio terminates a phase I/II trial in Urogenital cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in USA (IV), due to slow accrual (NCT04639245)
  • 27 May 2022 SignalOne Bio in collaboration with Fred Hutchinson Cancer Center suspends a phase I/II trial in Urogenital cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT04639245)
  • 15 Mar 2021 Phase-I/II clinical trials in Breast cancer (Combination therapy, Metastatic disease, Late-stage disease, Second-line therapy or greater) in USA (IV) (NCT04639245)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top